NCT03754309: A trial that was reported late by Kymab Limited
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT03754309 |
|---|---|
| Title | A Phase 2a, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 13, 2018 |
| Completion date | May 12, 2020 |
| Required reporting date | May 12, 2023, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Jan. 30, 2023 |
| Days late | None |